Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Cheng-fu Sun x
Clear All Modify Search
Open access

Tie-long Zheng, Ping-an Wang, Dian-li Wang, Cheng-fu Sun, Yuan Hong, Qi Wang and Jun Cheng

Abstract

Objective To observe the biological function of human 3-hydroxyisobutyrate dehydrogenase (HIBADH).

Methods Human 3-hydroxyisobutyrate dehydrogenase (HIBADH, 3-hydroxy-2-methyl propanoate: NAD+ oxidoreductase) recombinant protein was expressed in E. coli BL21, and purified by Ni+ column. The special antisera was obtained from rabbits immunized by this purified antigen. On the distribution of HIBADH, it was found that HIBADH over-expressed in the injured liver cells when serious hepatitis occurred. The phenomenon was confirmed in the animal models of SD rats with acute liver cell injury induced by CCl4, but this phenomenon did not exist in the models induced by endotoxin combined with galactosamine. Further more, HIBADH’s overexpression in liver cells will induce cell necrosis through the pathway of oxidative stress.

Results When the liver cells injured by drug or other chemical materials, HIBADH will be compensationally over-expressed for the deficiency of energy, so liver cells can make enough ATP through brand-chain amino acid catabolism. However, the overexpression of HIBADH will be harmful for liver cells through the product of much more active oxygens which will induce the cell necrosis.

Conclusions HIBADH over-expression is a signal of the liver cell metabolism injury, and it can aggravate the liver cell injury through oxidative stress.

Open access

Ren-Nan Feng, Cheng Wang, Chang-Hao Sun, Fu-Chuan Guo, Chen Zhao and Ying Li

Abstract

Background: Visceral adipose tissue-derived serine protease inhibitor (vaspin) is a novel adipocytokine. Several studies have indicated that vaspin may exert an important role in the development of metabolic disorders.

Objective: Evaluate serum vaspin and its relation to clinical parameters in newly and previously diagnosed Chinese type 2 diabetes mellitus (T2DM) females as a case-control study.

Materials and methods: One hundred twenty female participants (newly and previously diagnosed T2DM patients) were recruited from an affiliated hospital of Harbin Medical University. Sixty healthy female volunteers from various communities were included as controls. Anthropometric parameters, serum fasting blood glucose, fasting insulin, lipid profile, HbA1c, and vaspin were measured in each participant.

Results: Serum vaspin levels were significantly lower in previously diagnosed T2DM patients (0.51±0.29 ng/mL) than in newly diagnosed T2DM patients (0.62±0.28 ng/mL) and healthy controls (0.69±0.31 ng/mL). However, there was no difference in serum vaspin between newly diagnosed T2DM patients and healthy controls. In multiple linear regression analysis, serum vaspin was significantly and positively associated with HbA1c in both newly and previously diagnosed T2DM patients, negatively associated with homeostasis model assessment of insulin resistance in previously diagnosed patients, and positively correlated with age and body mass index in healthy controls.

Conclusion: Serum vaspin was significantly lower in previously diagnosed T2DM patients than in newly diagnosed T2DM patients and healthy controls. Serum vaspin might be a predictor of poor glucose control and insulin resistance in T2DM.